[
  {
    "ts": null,
    "headline": "IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma",
    "summary": "NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizum",
    "url": "https://finnhub.io/api/news?id=b41c9b6039b4e0a690f686c4b3ba7eab03444d3c2916e23ca796b2a1a0a8ef54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754827200,
      "headline": "IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma",
      "id": 136294332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizum",
      "url": "https://finnhub.io/api/news?id=b41c9b6039b4e0a690f686c4b3ba7eab03444d3c2916e23ca796b2a1a0a8ef54"
    }
  },
  {
    "ts": null,
    "headline": "2 Magnificent Stocks to Buy That Are Near 52-Week Lows",
    "summary": "These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.",
    "url": "https://finnhub.io/api/news?id=3baaf5aff03fd9f91041a20f551e7b299d756ee0e665bbe0af367c1f98bcdc83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754818800,
      "headline": "2 Magnificent Stocks to Buy That Are Near 52-Week Lows",
      "id": 136292386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.",
      "url": "https://finnhub.io/api/news?id=3baaf5aff03fd9f91041a20f551e7b299d756ee0e665bbe0af367c1f98bcdc83"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August",
    "summary": "One reliable high-yielder, one dividend growth stock, and one turnaround story for dividend lovers in August.",
    "url": "https://finnhub.io/api/news?id=1530f1c6ceb29fb0fbd6da8ed08c38d40c3b7dda4666de07ad10f227f163352a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754815200,
      "headline": "3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August",
      "id": 136292387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "One reliable high-yielder, one dividend growth stock, and one turnaround story for dividend lovers in August.",
      "url": "https://finnhub.io/api/news?id=1530f1c6ceb29fb0fbd6da8ed08c38d40c3b7dda4666de07ad10f227f163352a"
    }
  },
  {
    "ts": null,
    "headline": "BofA Kept $200 Target on Zoetis (ZTS) as Competitive Threat Seen Modest",
    "summary": "Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America analyst Michael Ryskin reaffirmed a Buy rating on Zoetis with an unchanged price target of $200. His view remains constructive despite the recent FDA approval of Merck’s Bravecto Quantum, a new product that some […]",
    "url": "https://finnhub.io/api/news?id=1bdece107f60a0614a30df0226651d0fcff64115762c14686360ad72455fb656",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754798392,
      "headline": "BofA Kept $200 Target on Zoetis (ZTS) as Competitive Threat Seen Modest",
      "id": 136292388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America analyst Michael Ryskin reaffirmed a Buy rating on Zoetis with an unchanged price target of $200. His view remains constructive despite the recent FDA approval of Merck’s Bravecto Quantum, a new product that some […]",
      "url": "https://finnhub.io/api/news?id=1bdece107f60a0614a30df0226651d0fcff64115762c14686360ad72455fb656"
    }
  }
]